Key Points
- Insider transaction: Zhenyu Xu sold 4,000 SOPHiA GENETICS shares at an average price of $7.52, generating $30,080. The sale was conducted under a pre-arranged Rule 10b5-1 plan, leaving Xu with 586,887 shares.
- Recent performance: SOPH opened at $7.50, near its 52-week high of $7.88, but remains unprofitable. Its latest quarterly loss of $0.26 per share missed estimates, although revenue of $23.31 million exceeded expectations.
- Analyst outlook: Institutional investors own 31.59% of the company, while analyst coverage is mixed but carries a consensus “Hold” rating and a $10.00 price target; HC Wainwright and BTIG both recently raised their targets.
SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $7.52, for a total transaction of $30,080.00. Following the completion of the sale, the insider owned 586,887 shares in the company, valued at $4,413,390.24. The trade was a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Zhenyu Xu also recently made the following trade(s):
- On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
- On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total value of $21,000.00.
- On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.
- On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $22,800.00.
- On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total value of $38,221.81.
SOPHiA GENETICS Stock Down 1.6%
SOPH stock opened at $7.50 on Friday. The company has a market cap of $629.17 million, a price-to-earnings ratio of -6.52 and a beta of 0.96. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $7.88. The business has a 50 day moving average price of $5.89 and a two-hundred day moving average price of $5.23. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.
Institutional Investors Weigh In On SOPHiA GENETICS
Hedge funds have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC raised its position in shares of SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the period. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth about $9,809,000. Principal Financial Group Inc. lifted its stake in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock worth $6,976,000 after buying an additional 9,800 shares during the last quarter. Finally, Archon Capital Management LLC boosted its holdings in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock worth $2,061,000 after buying an additional 14,342 shares during the period. Institutional investors and hedge funds own 31.59% of the company's stock.
Wall Street Analysts Forecast Growth
SOPH has been the topic of several recent analyst reports. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. BTIG Research lifted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, SOPHiA GENETICS presently has a consensus rating of "Hold" and a consensus price target of $10.00.
View Our Latest Analysis on SOPHiA GENETICS
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
